Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 26 May 2026 09:30:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 26 May 2026 09:30:00 -0400

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 26 May 2026 09:30:00 -0400

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 26 May 2026 09:30:00 -0400

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Wed, 20 May 2026 08:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Wed, 20 May 2026 08:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Wed, 20 May 2026 08:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Wed, 20 May 2026 08:00:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET.

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26506042.html

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: Redmile Group, LLC

Fri, 15 May 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260515/26506042.html

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:15:00 -0400

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock.

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.

The Plan, initially adopted by the Company’s board

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:15:00 -0400

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.

The Plan, initially adopted by the Company’s board

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:15:00 -0400

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.

The Plan, initially adopted by the Company’s board

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 15 May 2026 16:15:00 -0400

The awards are subject to all terms and conditions and other provisions set forth in the Company’s 2022 Inducement Equity Plan (the “Plan”) and the award agreements thereunder.

The Plan, initially adopted by the Company’s board

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501318.html

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Fri, 15 May 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260515/26501318.html

Scholar Rock (SRRK) PT Raised to $65 at H.C. Wainwright

Fri, 08 May 2026 07:00:16 -0400

H.C. Wainwright analyst Andres Maldonado raised the price target on Scholar Rock (NASDAQ: SRRK) to $65.00 (from $58.00) while maintaining a Buy rating.

Scholar Rock (SRRK) PT Raised to $55 at Barclays

Fri, 08 May 2026 04:07:57 -0400

Barclays analyst Etzer Darout raised the price target on Scholar Rock (NASDAQ: SRRK) to $55.00 (from $53.00) while maintaining a Overweight rating.

Scholar Rock Holding Corp. (SRRK) Misses Q1 EPS by 3c

Thu, 07 May 2026 07:22:18 -0400

Scholar Rock Holding Corp. (NASDAQ: SRRK) reported Q1 EPS of ($0.83), $0.03 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Scholar Rock Holding Corp. (SRRK) click here.

Form 10-Q Scholar Rock Holding For: Mar 31

Thu, 07 May 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26448154.html

Form 10-Q Scholar Rock Holding For: Mar 31

Thu, 07 May 2026 07:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26448154.html

Form 8-K Scholar Rock Holding For: May 07

Thu, 07 May 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26448039.html

Form 8-K Scholar Rock Holding For: May 07

Thu, 07 May 2026 07:10:00 -0400

si-local-file:///var/storage/secattach/20260507/26448039.html

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Thu, 07 May 2026 07:00:00 -0400

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date
Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and a second U.S.-based facility
FDA has completed reinspection of Catalent Indiana; classification of facility expected within 90 days following reinspection, in accordance with FDA guidelines
Second fill-finish facility on track to have commercial apitegromab supply in early Q3 2026
Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Thu, 07 May 2026 07:00:00 -0400

FDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date

Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and a second U.S.-based facility

FDA has completed reinspection of Catalent Indiana; classification of facility expected within 90 days following reinspection, in accordance with FDA guidelines

Second fill-finish facility on track to have commercial apitegromab supply in early Q3 2026

Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time

StreetInsider.com News Articles

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: Redmile Group, LLC

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: Redmile Group, LLC

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Form SCHEDULE 13G/A Scholar Rock Holding Filed by: PRICE T ROWE ASSOCIATES INC /MD/

Scholar Rock (SRRK) PT Raised to $65 at H.C. Wainwright

Scholar Rock (SRRK) PT Raised to $55 at Barclays

Scholar Rock Holding Corp. (SRRK) Misses Q1 EPS by 3c

Form 10-Q Scholar Rock Holding For: Mar 31

Form 10-Q Scholar Rock Holding For: Mar 31

Form 8-K Scholar Rock Holding For: May 07

Form 8-K Scholar Rock Holding For: May 07

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights